The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...

Celltrion launches ADC cancer drug trials in U.S. while planning additional INDs Celltrion accelerates its global drug ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Celltrions Vegzelma becomes Europes top prescribed anticancer drug in two years Celltrions cancer treatment Vegzelma achieves impressive market dominance in Europe within two years ...

Jersey City, New Jersey Saturday, February 1, 2025, 16:00 Hrs [IST] ...

The new biosimilar, Celltrion’s Avtozma, was approved in both IV and subcutaneous forms to treat inflammatory conditions such as arthritis.

The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

The two products, both manufactured by Amgen, are aflibercept biosimilars Pavblu and Skojoy. Both biosimilars are indicated ...

The US Food and Drug Administration (FDA) has approved Avtozma (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and ...